- Home
- MAZE vs IGD Comparison
MAZE vs IGD Comparison
Compare MAZE & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- IGD
- Stock Information
- Founded
- MAZE 2018
- IGD N/A
- Country
- MAZE United States
- IGD United States
- Employees
- MAZE N/A
- IGD N/A
- Industry
- MAZE
- IGD Trusts Except Educational Religious and Charitable
- Sector
- MAZE
- IGD Finance
- Exchange
- MAZE NYSE
- IGD Nasdaq
- Market Cap
- MAZE 367.0M
- IGD 422.7M
- IPO Year
- MAZE 2025
- IGD N/A
- Fundamental
- Price
- MAZE $9.86
- IGD $5.63
- Analyst Decision
- MAZE Strong Buy
- IGD
- Analyst Count
- MAZE 3
- IGD 0
- Target Price
- MAZE $25.67
- IGD N/A
- AVG Volume (30 Days)
- MAZE 199.0K
- IGD 215.3K
- Earning Date
- MAZE 01-01-0001
- IGD 01-01-0001
- Dividend Yield
- MAZE N/A
- IGD 9.15%
- EPS Growth
- MAZE N/A
- IGD N/A
- EPS
- MAZE 1.25
- IGD N/A
- Revenue
- MAZE $167,500,000.00
- IGD N/A
- Revenue This Year
- MAZE N/A
- IGD N/A
- Revenue Next Year
- MAZE N/A
- IGD N/A
- P/E Ratio
- MAZE $7.86
- IGD N/A
- Revenue Growth
- MAZE N/A
- IGD N/A
- 52 Week Low
- MAZE $6.71
- IGD $4.60
- 52 Week High
- MAZE $17.00
- IGD $5.26
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- IGD 56.59
- Support Level
- MAZE N/A
- IGD $5.58
- Resistance Level
- MAZE N/A
- IGD $5.62
- Average True Range (ATR)
- MAZE 0.00
- IGD 0.06
- MACD
- MAZE 0.00
- IGD 0.01
- Stochastic Oscillator
- MAZE 0.00
- IGD 89.13
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.